Cynata Therapeutics Ltd
F:51S
Cynata Therapeutics Ltd
F:51S
Price:
0.006
EUR
-14.29%
Market Closed
Market Cap:
€1.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cynata Therapeutics Ltd
F:51S
|
AU |
|
D
|
Dentsu Group Inc
XMUN:DEN
|
JP |
|
N
|
Nutrition SC PCL
SET:NTSC
|
TH |
|
B
|
Bhuwanatala Indah Permai Tbk PT
IDX:BIPP
|
ID |
|
R
|
Rabbit Holdings PCL
SET:RABBIT
|
TH |
|
S
|
Simat Technologies PCL
SET:SIMAT
|
TH |
|
T
|
Thai Eastern Group Holdings PCL
SET:TEGH
|
TH |
|
N
|
Nutrition Profess PCL
SET:NUT
|
TH |
|
H
|
Hisamitsu Pharmaceutical Co Inc
F:HPX
|
JP |
|
H
|
High Quality Food SpA
F:L24
|
IT |
|
A
|
AL Sydbank A/S
F:TM2
|
DK |
Intrinsic Value
Not Available for 51S
There is not enough data to reliably calculate the intrinsic value for Cynata Therapeutics Ltd.
Do our valuations actually work? See backtest results .
Alternatives to 51S
Fundamental Analysis
What Cynata Therapeutics Does
Cynata Therapeutics is a biotech company that develops cell-based medicines, mainly therapies built from mesenchymal stem cells, or MSCs. Its core idea is to make these cells from a master cell line rather than relying on donors one batch at a time. That matters because it is meant to give drug developers a more consistent and scalable source of cells for testing and treatment.
- Headquarters
- Australia AU
- IPO date
- Dec 20, 2007
Financials
Efficiency
Earnings Waterfall
Cynata Therapeutics Ltd
Cynata Therapeutics Ltd
